Have any questions? 706-721-6582 or cts@augusta.edu
- ACTIV-4C: A multicenter, adaptive, prospective, randomized trial evaluating the efficacy and safety of antithrombotic strategies in patients with COVID-19 following hospital discharge (Short title: COVID-19 Post-hospital Thrombosis Prevention Study)
Clinical Trial
ACTIV-4C: A multicenter, adaptive, prospective, randomized trial evaluating the efficacy and safety of antithrombotic strategies in patients with COVID-19 following hospital discharge (Short title: COVID-19 Post-hospital Thrombosis Prevention Study)
This study will enroll COVID-positive patients who are hospitalized with anticipated discharge within 2 days. It will evaluate the efficacy and safety of different anti-thrombotic treatments for these patients following discharge from the hospital.
- Respiratory System
- Antithrombotic
- Apixaban
- Coronavirus Disease (COVID
- COVID-19
- SARS-CoV-2)
- Thrombosis
Eligibility Criteria
- INCLUSION: 1. Adults age 18 years or older who are positive for COVID-19 and who have been hospitalized for at least 48 hours. EXCLUSION: 1. Current use of anticoagulant medications, or contraindications to taking anticoagulants. 2. Any labs, medications or medical conditions not allowed by the study
RESEARCH. INNOVATION. DISCOVERY.